Researchers tested a type of stem cell treatment called non-myeloablative allogeneic stem cell transplantation (allo-NST) on 26 patients with blood cancers.
Most patients (84.62%) successfully accepted the transplant, and only a few experienced serious side effects like graft-versus-host disease (GVHD).
The study suggests that allo-NST is a safe and effective way to treat these cancers, but more research is needed on the treatment details.